Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Market Cap	56.87B
Revenue (ttm)	32.41B
Net Income (ttm)	4.92B
Shares Out	41.63M
EPS (ttm)	118.28
PE Ratio	11.55
Forward PE	12.44
Dividend	50.00 (3.58%)
Ex-Dividend Date	Sep 29, 2025

Volume	31,100
Average Volume	223,270
Open	1,367.00
Previous Close	1,366.00
Day's Range	1,357.00 - 1,368.00
52-Week Range	970.00 - 1,897.00
Beta	-0.33
RSI	46.37
Earnings Date	Aug 5, 2025

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,436
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2395

Financial Performance

In 2024, TYO:2395's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.